RayKnowChina Research Map
Shortlist

Shanghai

Shuguang Hospital

上海中医药大学附属曙光医院

Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shuguang Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌20 papers led
  2. Osteosarcoma骨肉瘤1 paper led
  3. Neuroblastoma神经母细胞瘤0 papers led
  4. Ewing sarcoma尤文肉瘤0 papers led
  5. Haemophilia A血友病 A1 paper led
  6. Fanconi anaemia范可尼贫血1 paper led
  7. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  8. IgA nephropathyIgA 肾病3 papers led
  9. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  10. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 20 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 0020232024: 8820242025: 332025

16 hospitals in Shanghai for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineClinical trials / research unitMedical oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led20
  1. Circadian disruption in hepatocellular carcinoma: Current findings and future directions of molecular mechanisms.2026Drug discovery today
  2. Nervous system in hepatocellular carcinoma: Correlation, mechanisms, therapeutic implications, and future perspectives.2025Biochimica et biophysica acta. Reviews on cancer
  3. Jiedu Fang inhibits hypoxia-induced angiogenesis in hepatocellular carcinoma by targeting Aurora A/STAT3/IL-8 signaling pathway.2025Journal of integrative medicine
  4. Efficacy of Jiedu formula as adjuvant therapy for early recurrence of hepatocellular carcinoma after radical surgery: a propensity score matching study.2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  5. Construction of a prognostic model based on disulfidptosis-related genes and identification of CCNA2 as a novel biomarker for hepatocellular carcinoma.2024Biology directFree full text
  6. An herbal formula Shenlian decoction upregulates M1/M2 macrophage proportion in hepatocellular carcinoma by suppressing complement cascade.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. Curcumin promotes ferroptosis in hepatocellular carcinoma via upregulation of ACSL4.2024Journal of cancer research and clinical oncologyFree full text
  8. Anti-stromal nanotherapeutics for hepatocellular carcinoma.2024Journal of controlled release : official journal of the Controlled Release Society
  9. Identification of Erzhu Jiedu Recipe and its molecular mechanism underlying inhibited human hepatoma cells by UHPLC-Q-Exactive Orbitrap HRMS and network pharmacology.2024Journal of ethnopharmacology
  10. Integrating single-cell and bulk sequencing data to identify glycosylation-based genes in non-alcoholic fatty liver disease-associated hepatocellular carcinoma.2024PeerJFree full text
  11. Exploring the anti-hepatocellular carcinoma effects of Xianglian Pill: Integrating network pharmacology and RNA sequencing via in silico and in vitro studies.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  12. Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signaling.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  13. Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  14. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma.2022Journal for immunotherapy of cancerFree full text
  15. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  16. Differential diagnosis of different types of solid focal liver lesions using two-dimensional shear wave elastography.2022World journal of gastroenterologyFree full text
  17. Interpreting the Molecular Mechanisms of Yinchenhao Decoction on Hepatocellular Carcinoma through Absorbed Components Based on Network Pharmacology.2021BioMed research internationalFree full text
  18. Erzhu Qinggan Jiedu Recipe improves the clinical outcome of hepatocellular cancer after surgical resection: a case-control retrospective study.2021Internal medicine journal
  19. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  20. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway.2021Journal of ethnopharmacology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

45 hospitals in Shanghai for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. The crosstalk between LINC01089 and hippo pathway inhibits osteosarcoma progression.2022Journal of bone and mineral metabolism
Earlier papers (2016–2020)1
  1. FDG PET/CT in a Case of Primary Pulmonary Ewing Sarcoma.2019Clinical nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

27 hospitals in Shanghai for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. FDG PET/CT in a Case of Primary Pulmonary Ewing Sarcoma.2019Clinical nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Shanghai for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Shanghai for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025

26 hospitals in Shanghai for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

23 hospitals in Shanghai for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

16 hospitals in Shanghai for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

13 hospitals in Shanghai for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Total astragalus saponins attenuate primary sclerosing cholangitis in mice by upregulation of TGR5.2024Phytotherapy research : PTR
Chinese-language papers (not in the count)1
  1. [Application of Mdr2 gene knockout mice in liver disease research].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海中医药大学附属曙光医院

Shuguang Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data